NEW YORK, Nov. 19, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights…
Edwards Lifesciences Corporation investors that lost money on their investment are encouraged to contact BFA Law before December 13, 2024…
NEW YORK, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights…
Edwards Lifesciences Corporation investors that lost money on their investment are encouraged to contact BFA Law before December 13, 2024…
Die Edwards Lifesciences Aktie verzeichnete am 2. November 2024 einen erneuten Anstieg und setzte damit ihren positiven Trend der letzten…
Edwards Lifesciences Corporation investors that lost money on their investment are encouraged to contact BFA Law before December 13, 2024…
NEW YORK, Oct. 28, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights…
…
Edelson Lechtzin LLP announces the filing of a securities fraud class action on behalf of all purchasers of Edwards Lifesciences…
NEW YORK, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights…
SAN DIEGO, Oct. 19, 2024 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces that purchasers or…
EDWARDS LIFESCIENCES CORPORATION (NYSE: EW) INVESTOR ALERT: Investors With Large Losses in Edwards Lifesciences Should Contact Bernstein Liebhard LLP…
NEW YORK, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights…
SAN DIEGO, Oct. 14, 2024 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces that purchasers or…
Edward Lifesciences Critical Care divestiture bodes well for its Structural Heart portfolio. Yet, macroeconomic issues raise worry for its operations.…
Die Edwards Lifesciences Aktie verzeichnete am 21. September 2024 einen leichten Rückgang von 0,57% auf 66,84 USD. Trotz dieses kleinen…
…
BDX expands its smart care portfolio by acquiring Edwards Lifesciences Critical Care group, now BD Advanced Patient Monitoring, strengthening AI-driven…
Edward Lifesciences (EW) promising TAVR business and the Critical Care divestment move bode well in the long term.…
Edwards Lifesciences (EW) reports strong contributions from the TMTT product group in the second quarter of 2024.…
After-hours movers: Chipotle Mexican Grill, Ford, IBM, Edwards Lifesciences, and more…
The company now expects full-year sales in its TAVR division to climb 5% to 7%.…
Edwards Lifesciences (EW) exercises the option to acquire Innovalve Bio-Medical Ltd., strengthening its TMVR technology portfolio and addressing unmet…
Edwards Lifesciences (EW) TMTT segments PASCAL platform is likely to have maintained strong growth momentum in the second quarter…
…
Wenig Kursbewegung aktuell bei dem Anteilsschein von Edwards Lifesciences . Das Papier kostete zuletzt 91,47 US-Dollar. Die Wertschätzung der Investoren…
…
Edwards Lifesciences stock rallied Monday on medtech giant Becton Dickinsons plan to buy a key division for $4.2 billion.…
Edwards Lifesciences exec sells shares worth over $73k…
…
Salesforce, BP, The Southern, PayPal and Edwards Lifesciences are included in this Analyst Blog.…
Earnings call: Edwards Lifesciences sees robust Q1 growth, raises guidance…
Edwards Lifesciences stock maintains $100 target and Buy rating…
Dublin, April 19, 2024 (GLOBE NEWSWIRE) -- The "Cardiovascular Surgical Devices Market, Size, Share, Global Forecast 2024-2032, Industry…
Edwards Lifesciences exec sells over $1.1m in company stock…
Edwards Lifesciences executive sells over $2.7 million in stock…
Edwards Lifesciences (NYSE:EW) has had a great run on the share market with its stock up by a significant 23%…
Edwards Lifesciences shares target raised by Oppenheimer on valve therapy outlook…
Edwards Lifesciences (EW) outperforms the industry, owing to a robust 2023 fourth-quarter performance, as well as the strong potential in…
Shares of Edwards Lifesciences Corp. rose 2.22% to $92.93 Wednesday, on what proved to be an all-around mixed trading session…
Edwards Lifesciences (EW) recent study provides insights into the actual performance of small Edwards valves and reaffirms the excellent outcomes…
Edwards Lifesciences stock upgraded to buy, PT lifted to $105…
Edwards Lifesciences (EW) EVOQUE valve replacement system becomes the first transcatheter therapy to earn FDA approval for a tricuspid valve.…
FDA approves Edwards Lifesciences EVOQUE valve system…
Edwards Lifesciences (EW) Q4 results are likely to reflect continued demand for its state-of-the-art HemoSphere monitoring platform and Smart Recovery…
…
Edwards Lifesciences (EW) TAVR remains strong, driven by greater awareness, patient activation and advances in new technologies such as RESILIA.…
Edwards Lifesciences Corp.’s stock EW rose 1.9% in premarket trading Thursday after it said it plans to form an…
Edwards Lifesciences stock dips, ending four-day rally as market declines…
Edwards Lifesciences cut by Wolfe Research on risk of US TAVR disappointing…